main image

Nanoscale Combinatorial Synthesis and Euroscreen Announce Joint Drug Discovery Collaboration

Tucson, Ariz., January 17, 2000/PRNewsire/

Nanoscale Combinatorial Synthesis Inc. (Nanosyn) today announced that it will provide Euroscreen s.a. (Brussels, Belgium) with small molecule libraries designed for discovery research being conducted with Euroscreen's collection of cloned G-protein coupled receptors (GPCRs). The terms of the agreement include access to Nanosyn's capabilities in follow up synthesis and lead optimization.

"We are very pleased to have this opportunity to begin working with Euroscreen" notes Dr. Jim Ostrem, Vice President of Nanosyn. "Our company is founded on the concept that companies with interesting biology need access to a diverse compound collection for lead discovery as well as synthetic capabilities for lead optimization and scale up. The collaboration will combine our unique lead discovery libraries with Euroscreen's access to novel and proprietary receptors in a very important class of biological targets. This gives us the opportunity to maximize the potential of our in house collection and apply our proprietary synthesis platform to demonstrate the speed with which initial leads discovered in screening can be turned into high affinity ligands."

Dr. Pierre Nokin, Chief Executive Officer of Euroscreen, commented, "The goal of our company is to turn the large number of characterized and orphan G-protein coupled receptors which we have identified using PCR homology cloning into validated targets for drug discovery. Euroscreen has developed a broad technology base to functionally characterize these orphan receptors. In addition to various sources of biological compounds, we now have access to a collection of approximately 100,000 small molecule ligands that we can use to begin the process of identifying novel agonists and antagonists in high throughput screening assays at Euroscreen. Our goal is to provide pharmaceutical and biotechnology companies with both relevant receptors and small molecule ligands which can be used to validate the role these receptors play in disease processes."

Based in Tucson, Arizona, Nanosyn was established in 1998 by a group of scientists with extensive expertise in combinatorial organic synthesis, analysis of combinatorial libraries, and high throughput screening. The company has developed a proprietary platform for combinatorial synthesis, Accelerated Nanoscale Synthesis Technology (ANSTTM). ANSTTM streamlines the interface between the synthesis of diverse collections of organic compounds with drug-like characteristics and high throughput screening assays, dramatically reducing both the time and expense of modern lead discovery programs. For more information about Nanosyn's products and services see http://www.nanosyn.com

Euroscreen was founded in 1994 as a spin-off of the Brussels University School of Medicine. The founding scientists of the company, Drs.Gilbert Vassart and Marc Parmentier, are well known for their pioneering work in PCR based homology cloning. The company currently has more than one hundred cloned GPCRs in stable, transfected cell lines. A recent agreement with the University of Georgia Research Foundation gives the company exclusive world-wide rights for the use of aequorin-mediated light emission in high throughput screening assays to detect changes in intracellular calcium levels. More information about Euroscreen's products and services can be found at http://www.euroscreen.be

NANOSYN
(Nanoscale Combinatorial Synthesis Inc.)
625 Clyde Ave., Mountain View, CA 94043-2213 USA
Phone: 650-404-8050 Fax: 650-428-1770

Contact us at info@nanosyn.com